Adarza, with operations in Rochester, N.Y. and St. Louis, Missouri, is a leading developer and manufacturer of label-free biosensor assays and instruments servicing life science research, drug development and in vitro diagnostics customers. Adarza's products and services utilize its proprietary Arrayed Imaging ReflectometryTM ('AIR') detection platform that is capable of rapidly identifying and quantifying a series of biological target analyte species in a fluid sample, without chemical labels or complex processing. The AIR technology offers key performance benefits in sensitivity, speed, multiplex arrays, sample size, dynamic range, ease of use and industry-leading low cost of use. Adarza products address broad quantitative analyte detection applications, including cancer biomarkers, drug and vaccine development, allergy, immunology and infectious diseases research.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/04/14 | $6,800,000 | Series A |
Cultivation Capital Siemens Venture Capital | undisclosed |
| 03/22/16 | $5,000,000 | Series B |
Cultivation Capital Lewis & Clark Ventures | undisclosed |
| 02/04/20 | $25,000,000 | Series D |
3x5 Partners Lightchain Capital | undisclosed |
